EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results

Damien Pouessel, Soléakhéna Ken, Valérie Gouaze-Andersson, Lucie Piram, Augustin Mervoyer, Delphine Larrieu-Ciron, Bastien Cabarrou, Amélie Lusque, Marie Robert, Jean-Sebastien Frenel, Emmanuelle Uro-Coste, Pascale Olivier und 6 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad095 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2023. Verfasst von Damien Pouessel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Re-gaud, Toulouse, France. Hauptthemen laut MEDLINE: Glioblastoma, Re-Irradiation, Brain Neoplasms, Radiosurgery. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Institut Claudius Regaud, ARC Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypofractionated stereotactic radiotherapy (hFSRT) is a salvage option for recurrent glioblastoma (GB) which may synergize anti-PDL1 treatment. This phase I study evaluated the safety and the recommended phase II dose of anti-PDL1 durvalumab combined with hFSRT in patients with recurrent GB.

Methods

Patients were treated with 24 Gy, 8 Gy per fraction on days 1, 3, and 5 combined with the first 1500 mg Durvalumab dose on day 5, followed by infusions q4weeks until progression or for a maximum of 12 months. A standard 3 + 3 Durvalumab dose de-escalation design was used. Longitudinal lymphocytes count, cytokines analyses on plasma samples, and magnetic resonance imaging (MRI) were collected.

Results

Six patients were included. One dose limiting toxicity, an immune-related grade 3 vestibular neuritis related to Durvalumab, was reported. Median progression-free interval (PFI) and overall survival (OS) were 2.3 and 16.7 months, respectively. Multi-modal deep 
learning-based analysis including MRI, cytokines, and lymphocytes/neutrophil ratio isolated the patients presenting pseudoprogression, the longest PFI and those with the longest OS, but statistical significance cannot be established considering phase I data only.

Conclusion

Combination of hFSRT and Durvalumab in recurrent GB was well tolerated in this phase I study. These encouraging results led to an ongoing randomized phase II. (ClinicalTrials.gov Identifier: NCT02866747).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaRe-IrradiationBrain NeoplasmsRadiosurgeryHumansTreatment OutcomeNeoplasm Recurrence, LocalCytokinesAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Durvalumabdeep learninghypofractionated stereotactic re-irradiationphase I clinical trialrecurrent glioblastoma

Substanzen

CytokinesdurvalumabAntibodies, MonoclonalatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Re-gaud, Toulouse, France.
  • Department of Engineering and Medical Physics, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Regaud, Toulouse, France.
  • INSERM UMR1037, Centre de Recherche en Cancérologie de Toulouse (CRCT), Team Radiation Optimization "RADOPT", Toulouse, France.
  • Department of Radiation Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Regaud, Toulouse, France.
  • Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
  • Department of Biostatistics, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Regaud, Toulouse, France.

Förderung

  • Institut Claudius Regaud
  • ARC Foundation

Zitieren

APA

Pouessel, D., Ken, S., Gouaze-Andersson, V., Piram, L., Mervoyer, A., Larrieu-Ciron, D., Cabarrou, B., Lusque, A., Robert, M., Frenel, J. S., Uro-Coste, E., Olivier, P., Mounier, M., Sabatini, U., Sanchez, E. H., Zouitine, M., Berjaoui, A., & Cohen-Jonathan Moyal, E. (2023). Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results. The Oncologist. https://doi.org/10.1093/oncolo/oyad095

Vancouver

Pouessel D, Ken S, Gouaze-Andersson V, Piram L, Mervoyer A, Larrieu-Ciron D, et al. Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results. The Oncologist. 2023. doi:10.1093/oncolo/oyad095

BibTeX
@article{Pouessel2023,
  author = {Pouessel, Damien and Ken, Soléakhéna and Gouaze-Andersson, Valérie and Piram, Lucie and Mervoyer, Augustin and Larrieu-Ciron, Delphine and Cabarrou, Bastien and Lusque, Amélie and Robert, Marie and Frenel, Jean-Sebastien and Uro-Coste, Emmanuelle and Olivier, Pascale and Mounier, Muriel and Sabatini, Umberto and Sanchez, Eduardo Hugo and Zouitine, Mehdi and Berjaoui, Ahmad and Cohen-Jonathan Moyal, Elizabeth},
  title = {Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad095}
}
Kostenlos starten →